Product Highlight - Rivaroxaban (Xafariv)
25 Aug 2026
The XFactor in Stroke Prevention with Non-Valvular Atrial Fibrillation1,2
- Convenience – Once daily dosing1,2
- Comprehensive Care – From treatment to secondary prevention3,4
- Confidence – Backed up by studies involving thousands of patients5-7
References:
1. Rivaroxaban (Xafariv) 15mg Product Information, Version 0, October 2020.
2. Rivaroxaban (Xafariv) 20mg Product Information, Version 0, October 2020.
3. Trohman RG, Huang HD, Sharma PS. Atrial Fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1. Front Cardiovasc Med. 2023;10:1060030.
4. National Library of Medicine. Direct Oral Anticoagulants: A Quick Guide. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6206466/. Accessed 06 July 2026.
5. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
6. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676.
7. NICE. Atrial fibrillation: diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng196. Accessed 10 July 2026.
8. CHEST 2018 - Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. DOI:10.1016/j.chest.2018.07.040.
VIATRIS PHARMACEUTICALS, INC.
22nd Flr Units C&D, Menarco Tower,
32nd St Bonifacio Global City, Taguig City
Phone: (+63-2) 5318 5300
Website: www.viatris.com
